Market Newsdesk

Golden Ocean Group Limited (the “Company”) announces that its 2025 Annual General Meeting will be held on May 8, 2025. A copy of the Notice of Annual General Meeting and associated information including the Company`s Consolidated Financial Statements on Form 20-F for 2024 can be found on our website at www.goldenocean.bm and in the links below.

April 10, 2025

The Board of Directors
Golden Ocean Group Limited
Hamilton, Bermuda

This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act.

 

Attachments

• GOGL – 2025 AGM Notice
• GOGL – 2024 20F

CNH announces Chief Financial Officer transition

Basildon, April 10, 2025

CNH (NYSE: CNH) announces that Oddone Incisa, the Company’s current Chief Financial Officer (CFO), will step down and will be succeeded by James (Jim) Nickolas. Mr. Nickolas will be based at the Company’s North American headquarters in Oak Brook, Illinois, USA and will present the financial portion of the Company’s Strategic Business Plan at our Investor Day on May 8, 2025.

Jim Nickolas has over 30 years of experience in corporate finance, M&A, business strategy, tax and investment banking. He most recently served as CFO and Executive Vice President at Martin Marietta, a US-based supplier of construction materials. Prior to this, he spent close to a decade at construction multinational Caterpillar where his previous roles included Head of Corporate Development and Caterpillar Ventures, CFO of the Resources Industries segment, and CFO of the Global Mining unit.

Oddone Incisa has decided to pursue new opportunities outside of the organization. His 28-year career with CNH and the former Fiat Group (now Stellantis) has seen him work across Europe, North America and South America, assuming roles of increasing seniority in the Finance and Commercial Lending divisions.

Mr. Incisa and Mr. Nickolas will work side by side through April to ensure a seamless transition, with Mr. Nickolas taking full responsibility as CFO as of May 6, 2025.

“On behalf of our Board of Directors and Global Leadership Team, I wish to sincerely thank Oddone for his contributions and dedication to CNH over these many years. As CFO, he has played a key role in guiding the Company through many challenges including the Covid-19 pandemic, the demerger of our off- and on-highway business segments, the inclusion in US stock indexes and periods of both record performance and cyclical downturns. We wish him well in his future endeavors,” said Gerrit Marx, Chief Executive Officer at CNH. “We look forward to welcoming Jim to the team. He brings extensive finance and M&A expertise that will help drive and support our growth ambitions.”

CNH Industrial

(NYSE: CNH) is a world-class equipment, technology and services company. Driven by its purpose of Breaking New Ground, which centers on Innovation, Sustainability and Productivity, the Company provides the strategic direction, R&D capabilities, and investments that enable the success of its global and regional Brands. Globally,

Case IH

and

New Holland

supply 360° agriculture applications from machines to implements and the digital technologies that enhance them; and

CASE

and

New Holland Construction Equipment

deliver a full lineup of construction products that make the industry more productive. The Company’s regionally focused Brands include:

STEYR

, for agricultural tractors;

Raven

, a leader in digital agriculture, precision technology and the development of autonomous systems;

Hemisphere

, a leading designer and manufacturer of high-precision satellite-based positioning, and heading technologies;

Flexi-Coil

, specializing in tillage and seeding systems;

Miller

, providing tillage, seeding and hay & forage implements; and

Eurocomach,

producing a wide range of
mini and midi excavators for the construction sector, including electric solutions.

Across a history spanning over two centuries, CNH has always been a pioneer in its sectors and continues to passionately innovate and drive customer efficiency and success. As a truly global company, CNH’s 35,000+ employees form part of a diverse and inclusive workplace, focused on empowering customers to grow, and build, a better world.

For more information and the latest financial and sustainability reports visit:

cnh.com

For news from CNH and its Brands visit:

media.cnh.com

Contacts:

Media Relations

Email: [email protected]

Investor Relations

Email: [email protected]

Forward-looking Statements

All statements other than statements of historical fact contained in this press release
including competitive strengths; business strategy; future financial position or operating results; budgets; projections with respect to revenue, income, earnings (or loss) per share, capital expenditures, dividends, liquidity, capital structure or other financial items; costs; and plans and objectives of management regarding operations and products, are forward-looking statements. Forward-looking statements also include statements regarding the future performance of CNH and its subsidiaries on a standalone basis. These statements may include terminology such as “may”, “will”, “expect”, “could”, “should”, “intend”, “estimate”, “anticipate”, “believe”, “outlook”, “continue”, “remain”, “on track”, “design”, “target”, “objective”, “goal”, “forecast”, “projection”, “prospects”, “plan”, or similar terminology. Forward-looking statements are not guarantees of future performance. Rather, they are based on current views and assumptions and involve known and unknown risks, uncertainties and other factors, many of which are outside our control and are difficult to predict. If any of these risks and uncertainties materialize (or they occur with a degree of severity that the Company is unable to predict) or other assumptions underlying any of the forward-looking statements prove to be incorrect, including any assumptions regarding strategic plans, the actual results or developments may differ materially from any future results or developments expressed or implied by the forward-looking statements.

Factors, risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements include, among others: economic conditions in each of our markets, including the significant uncertainty caused by geopolitical events; production and supply chain disruptions, including industry capacity constraints, material availability, and global logistics delays and constraints; the many interrelated factors that affect consumer confidence and worldwide demand for capital goods and capital goods-related products, changes in government policies regarding banking, monetary and fiscal policy; legislation, particularly pertaining to capital goods-related issues such as agriculture, the environment, debt relief and subsidy program policies, trade and commerce and infrastructure development; government policies on international trade and investment, including sanctions, import quotas, capital controls and tariffs; volatility in international trade caused by the imposition of tariffs, sanctions, embargoes, and trade wars; actions of competitors in the various industries in which we compete; development and use of new technologies and technological difficulties; the interpretation of, or adoption of new, compliance requirements with respect to engine emissions, safety or other aspects of our products; labor relations; interest rates and currency exchange rates; inflation and deflation; energy prices; prices for agricultural commodities and material price increases; housing starts and other construction activity; our ability to obtain financing or to refinance existing debt; price pressure on new and used equipment; the resolution of pending litigation and investigations on a wide range of topics, including dealer and supplier litigation, intellectual property rights disputes, product warranty and defective product claims, and emissions and/or fuel economy regulatory and contractual issues; security breaches, cybersecurity attacks, technology failures, and other disruptions to the information technology infrastructure of CNH and its suppliers and dealers; security breaches with respect to our products; our pension plans and other post-employment obligations; political and civil unrest; volatility and deterioration of capital and financial markets, including pandemics (such as the COVID-19 pandemic), terrorist attacks in Europe and elsewhere; the remediation of a material weakness; our ability to realize the anticipated benefits from our business initiatives as part of our strategic plan; including targeted restructuring actions to optimize our cost structure and improve the efficiency of our operations; our failure to realize, or a delay in realizing, all of the anticipated benefits of our acquisitions, joint ventures, strategic alliances or divestitures and other similar risks and uncertainties, and our success in managing the risks involved in the foregoing.

Forward-looking statements are based upon assumptions relating to the factors described in this
press release,
which are sometimes based upon estimates and data received from third parties. Such estimates and data are often revised. Actual results may differ materially from the forward-looking statements as a result of a number of risks and uncertainties, many of which are outside CNH’s control. CNH expressly disclaims any intention or obligation to provide, update or revise any forward-looking statements in this announcement to reflect any change in expectations or any change in events, conditions or circumstances on which these forward-looking statements are based.

Further information concerning CNH, including factors that potentially could materially affect its financial results, is included in the Company’s reports and filings with the U.S. Securities and Exchange Commission (“SEC”).

All future written and oral forward-looking statements by CNH or persons acting on the behalf of CNH are expressly qualified in their entirety by the cautionary statements contained herein or referred to above.

Additional factors could cause actual results to differ from those expressed or implied by the forward-looking statements included in the Company’s filings with the SEC (including, but not limited to, the factors discussed in our 2024 Annual Report and subsequent quarterly reports).

Attachment

• 20250410_PR_CNH_CFO_Announcement

NEW YORK, April 10, 2025 (GLOBE NEWSWIRE) — Cornerstone Strategic Investment Fund, Inc. (NYSE American: CLM) (CUSIP: 21924B302) (the “Fund”) announced today that, contingent upon final approval from the U.S. Securities and Exchange Commission (“SEC”), it has set the close of business on April 21, 2025 as the record date (the “Record Date”) for determination of stockholders entitled to participate in the Fund’s 1-for-3 rights offering. The Fund is issuing to its stockholders non-transferable rights entitling the holders to subscribe for an aggregate of 84,252,329 shares of common stock. Each stockholder will receive one non-transferable right for each share of the Fund held as of the Record Date.  Fractional shares will not be issued upon the exercise of the rights. Accordingly, the number of rights to be issued to a stockholder on the Record Date will be rounded up to the nearest whole number of rights evenly divisible by three. For every three rights a stockholder receives, he or she will be entitled (but not required) to purchase one new share of the Fund at a subscription price equal to the greater of (i) 112% of net asset value per share as calculated at the close of trading on the expiration date of the offering or (ii) 80% of the market price per share at such time.  Fractional shares will not be issued.  In addition to the shares offered in the primary subscription, the Fund may offer a 100% over-allotment to oversubscribing stockholders.  Stockholders who fully subscribe in the primary offering will have the option to oversubscribe for additional shares, to the extent available.

The subscription period will commence shortly after the Record Date, and will expire at 5:00 p.m., EDT, on Friday, May 16, 2025, (the “Expiration Date”) unless extended. The actual subscription price per share will be determined on the Expiration Date.

Shares will be issued within the 15-day period immediately following the record date of the Fund’s May 2025 monthly distribution to stockholders. Stockholders exercising their rights to purchase shares pursuant to the offering will not be entitled to receive such distribution with respect to the shares issued pursuant to such exercise.

This press release is not intended to and does not constitute an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities in any jurisdiction, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. The offering is subject to an effective registration statement covering the rights and shares to be issued and to other customary regulatory filings and approvals.  Any rights offering conducted by the Fund will be made only by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

Cornerstone Strategic Investment Fund, Inc. is a closed-end, diversified management investment company and is registered with the SEC under the Investment Company Act of 1940, as amended.

Cornerstone Strategic Investment Fund, Inc. is traded on the NYSE American LLC under the trading symbol “CLM”. The Fund’s investment adviser is Cornerstone Advisors, LLC, which also serves as the investment adviser to another closed-end fund, Cornerstone Total Return Fund, Inc. (NYSE American: CRF). For more information regarding Cornerstone Strategic Investment Fund, Inc. or Cornerstone Total Return Fund, Inc. please visit www.cornerstonestrategicinvestmentfund.com, and www.cornerstonetotalreturnfund.com.

Past performance is no guarantee of future performance. An investment in the Fund is subject to certain risks, including market risk. In general, shares of closed-end funds often trade at a discount from their net asset value and at the time of sale may be trading on the exchange at a price which is more or less than the original purchase price or the net asset value. An investor should carefully consider the Fund’s investment objective, risks, charges and expenses. Please read the Fund’s disclosure documents before investing.

In addition to historical information, this release contains forward-looking statements, which may concern, among other things, domestic and foreign markets, industry and economic trends and developments and government regulation and their potential impact on the Fund’s investment portfolio. These statements are subject to risks and uncertainties, including the factors set forth in the Fund’s disclosure documents, filed with the U.S. Securities and Exchange Commission, and actual trends, developments and regulations in the future, and their impact on the Fund could be materially different from those projected, anticipated or implied. The Fund has no obligation to update or revise forward-looking statements.

Contact: (866) 668-6558

WESTLAKE VILLAGE, Calif., April 10, 2025 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that David Topper, Arcutis’ chief financial officer (CFO) is retiring from the Company and Latha Vairavan, currently vice president and controller, will assume the role of CFO and join the executive team as part of a planned succession. Mr. Topper will continue to serve as CFO until the filing of the Company’s first quarter 10-Q and will provide transition support through his departure on May 15, 2025.

Mr. Topper, who has served as the Company’s CFO since April 2024, has been instrumental in strengthening Arcutis’ financial position, which has enabled the Company to continue investing in its future growth. Most notably, he renegotiated the Company’s existing debt facility with SLR Investment Corp., revamped the Company’s overall investor relations strategy, and led the Company’s transition to a large accelerated filer subject to Sarbanes-Oxley Section 404(b) reporting requirements.

“On behalf of the Board of Directors and our entire leadership team, I would like to extend our gratitude to David for his contributions to Arcutis, both during his time as our CFO and prior to that, as a strategic advisor to the Company,” said Frank Watanabe, Arcutis president and CEO. “David has made numerous important contributions to our financial organization that have left Arcutis in a much stronger financial position, and which have prepared us for the exciting period of growth ahead of us.”

“I am delighted to be able to announce that Latha will succeed David as CFO,” Watanabe continued. “We are confident that with her deep understanding of our business, broad professional experience, and strong relationships across our entire organization and industry, she will be able to build on the strong foundation and lead our financial operations effectively.”

“It’s been an honor to work at Arcutis over the past year. Very few biopharma companies reach the level of commercial success that Arcutis has attained. This is due in no small way to the very strong team which is top notch in every way. The market momentum that the company and ZORYVE^® (roflumilast) are demonstrating is impressive and I’m confident will continue for years to come,” said David Topper.

Ms. Vairavan has over 20 years of finance and accounting professional experience in the biotech industry. She joined Arcutis in 2020 to lead financial planning and analysis, and later served as vice president of finance and investor relations before assuming her current role as vice president, finance and corporate controller, where she has been responsible for overseeing daily accounting operations, ensuring compliance with financial, accounting, and income tax regulations, managing all investor relations activities, and overseeing financial planning and analysis. Previously, Ms. Vairavan was at Amgen for 12 years, where she held various roles of increasing responsibility within the finance organization, culminating as finance director for U.S. value and access. Ms. Vairavan started her career as a financial consultant working for KPMG and Arthur Andersen. She holds a BS in Business Administration, Finance, from the University of Southern California, and is a licensed CPA in California.

“I am excited to take on the role as CFO as we launch and further commercialize ZORYVE in multiple inflammatory skin conditions and build upon our strong financial position,” said Latha Vairavan. “Having been part of the team for several years, I’ve witnessed firsthand the incredible momentum we’re building, and I look forward to helping drive our continued growth and financial strength.”

About Arcutis

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis has a growing portfolio including three FDA approved products that harness our unique dermatology development platform coupled with our dermatology expertise to build differentiated therapies against biologically validated targets. Arcutis’ dermatology development platform includes a robust pipeline with multiple clinical programs for a range of inflammatory dermatological conditions including scalp and body psoriasis, atopic dermatitis, and alopecia areata. For more information, visit www.arcutis.com or follow Arcutis on LinkedIn, Facebook, Instagram and X.

INDICATIONS

ZORYVE cream, 0.3%, is indicated for topical treatment of plaque psoriasis, including intertriginous areas, in adult and pediatric patients 6 years of age and older.

ZORYVE cream, 0.15%, is indicated for topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 6 years of age and older.

ZORYVE foam, 0.3%, is indicated for the treatment of seborrheic dermatitis in adult and pediatric patients 9 years of age and older.

IMPORTANT SAFETY INFORMATION

ZORYVE is contraindicated in patients with moderate to severe liver impairment (Child-Pugh B or C).

Flammability: The propellants in ZORYVE foam are flammable. Avoid fire, flame, and smoking during and immediately following application.

The most common adverse reactions (≥1%) for ZORYVE cream 0.3% for plaque psoriasis include diarrhea (3.1%), headache (2.4%), insomnia (1.4%), nausea (1.2%), application site pain (1.0%), upper respiratory tract infection (1.0%), and urinary tract infection (1.0%).

The most common adverse reactions (≥1%) for ZORYVE cream 0.15% for atopic dermatitis include headache (2.9%), nausea (1.9%), application site pain (1.5%), diarrhea (1.5%), and vomiting (1.5%).

The most common adverse reactions (≥1%) for ZORYVE foam 0.3% for seborrheic dermatitis include nasopharyngitis (1.5%), nausea (1.3%), and headache (1.1%).

Please see full Prescribing Information for ZORYVE cream and full Prescribing Information for ZORYVE foam.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. For example, statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company’s current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding the Company’s financial position and potential growth. These statements are subject to substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in our business, reimbursement and access to our products, the impact of competition and other important factors discussed in the “Risk Factors” section of our Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on February 25, 2025, as well as any subsequent filings with the SEC. Any forward-looking statements that the company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, we undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.

Contacts:

Media



Amanda Sheldon, Head of Corporate Communications
[email protected]

Investors



Latha Vairavan, VP Finance & Corporate Controller
[email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a4c82ab1-b754-4be2-952e-8aab8d2692d5

This press release was published by a CLEAR® Verified individual.

MIAMI, April 10, 2025 (GLOBE NEWSWIRE) — Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH) (together with NCL Corporation Ltd., “Norwegian Cruise Line Holdings” or the “Company”) announced today it will report first quarter 2025 financial results on Wednesday, April 30, 2025 at 6:30 a.m. Eastern Time with a conference call and webcast to discuss results at 8:00 a.m. Eastern Time.

The conference call will be webcast via the Company’s Investor Relations website, https://www.nclhltd.com/investors. A replay of the webcast will be available here on the Company’s website for 30 days following the call.

About Norwegian Cruise Line Holdings Ltd.

Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH) is a leading global cruise company that operates Norwegian Cruise Line, Oceania Cruises and Regent Seven Seas Cruises. With a combined fleet of 33 ships and approximately 70,050 berths, NCLH offers itineraries to approximately 700 destinations worldwide. NCLH expects to add 12 additional ships across its three brands through 2036, which will add over 37,500 berths to its fleet. To learn more, visit www.nclhltd.com.

Investor Relations and Media Contacts
Sarah Inmon (786) 812-3233
[email protected]

HAUPPAUGE, N.Y., April 10, 2025 (GLOBE NEWSWIRE) — Dime Community Bancshares, Inc. (NASDAQ: DCOM) (the “Company” or “Dime”), the parent company of Dime Community Bank (the “Bank”) announced that it has hired a deposit-focused Group that will cover the Queens market. The Group will be led by George Taitt and Amy Grandy. The Group was previously employed with the former Signature Bank and its successor, Flagstar Bank.

Stuart H. Lubow, President and Chief Executive Officer of Dime said, “We are excited to announce the addition of another talented deposit-focused Group. George and Amy are highly respected bankers with a long and successful track record. We continue to capitalize on the disruption in our marketplace and remain focused on executing our growth plan in a thoughtful and targeted manner.”

“We were attracted by Dime’s strong track record of bringing on new teams seamlessly, its bank-wide culture and belief in teamwork that leads to an exceptional client experience, and the Bank’s robust treasury management and technology capabilities. Both Amy and I are excited to be part of Dime’s growth plans,” said George Taitt.

ABOUT DIME COMMUNITY BANCSHARES, INC.

Dime Community Bancshares, Inc. is the holding company for Dime Community Bank, a New York State-chartered trust company with over $14 billion in assets and the number one deposit market share among community banks on Greater Long Island ⁽¹⁾.

Dime Community Bancshares, Inc.

Investor Relations Contact:
Avinash Reddy
Senior Executive Vice President – Chief Financial Officer
Phone: 718-782-6200; Ext. 5909
Email: [email protected]

¹ Aggregate deposit market share for Kings, Queens, Nassau & Suffolk counties for community banks with less than $20 billion in assets.

PITTSBURGH, April 10, 2025 (GLOBE NEWSWIRE) — Montauk Renewables, Inc. (“Montauk” or “the Company”) (NASDAQ: MNTK) announces that its subsidiary, Tulsa LFG, LLC broke ground on a Renewable Natural Gas (“RNG”) landfill gas project at the American Environmental Landfill, Inc. (“AEL”) in Tulsa, Oklahoma in a ceremony on Wednesday, April 9, 2025 (the “Project”).

The Project is accompanied by an extension of its existing gas rights and lease agreement with the landfill host, American Environmental Landfill, Inc. (“AEL”). With a variable inlet capacity design, the new RNG facility is anticipated to have a production nameplate capacity averaging approximately 1,500 MMBtu per day, capable of beneficially processing all of the available inlet gas feedstock from its host landfill, which has been meaningfully increasing through Montauk’s wellfield investment over the past year.

“Montauk is excited to announce the development of our new RNG facility in Tulsa, Oklahoma, in continued support of AEL, one of our most prized relationships in our portfolio,” said Sean McClain, Montauk Renewables CEO. “We believe this project is indicative of our core growth strategy, to align ourselves with exemplary host businesses, and synchronize their growth needs with our development initiatives. The strong historical and continued growth of available feedstock at this project location is a great example of how successful these partnerships can be.”

Montauk expects its project capital investment to range between $25 million to $35 million and has a targeted commissioning date in the first quarter of 2027. 

About Montauk Renewables, Inc.

Montauk Renewables, Inc. (NASDAQ: MNTK) is a renewable energy company specializing in the management, recovery and conversion of biogas into RNG. The Company captures methane, preventing it from being released into the atmosphere, and converts it into either RNG or electrical power for the electrical grid (“Renewable Electricity”). The Company, headquartered in Pittsburgh, Pennsylvania, has more than 30 years of experience in the development, operation and management of landfill methane-fueled renewable energy projects. The Company has operations at 13 projects and ongoing development projects located in California, Idaho, Ohio, Oklahoma, Pennsylvania, North Carolina, South Carolina, and Texas. The Company sells RNG and Renewable Electricity, taking advantage of Environmental Attribute premiums available under federal and state policies that incentivize their use. For more information, visit. https://ir.montaukrenewables.com

Company Contact:

John Ciroli
Chief Legal Officer (CLO) & Secretary
[email protected]
(412) 747-8700

Investor Relations Contact:

Georg Venturatos
Gateway Group
[email protected]
(949) 574-3860

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/3114c2cb-3a43-49a0-aa37-af485d21db34

https://www.globenewswire.com/NewsRoom/AttachmentNg/103e7888-8ca6-4d25-9cf3-c45659f3f484

https://www.globenewswire.com/NewsRoom/AttachmentNg/4577cfec-6301-4426-af59-ef56ad861f8c

New York, NY, April 10, 2025 (GLOBE NEWSWIRE) — Interpublic Group (NYSE: IPG) today announced that it will release earnings for the first quarter ended March 31, 2025 on the morning of April 24, 2025. Following the release, the company will hold a conference call for investors at 8:30 a.m. Eastern Time on the same day to review results.

To join the conference call, please call (888) 790-3345. Outside the United States, please call (517) 308-9030. The participant passcode is 6037460. The call will be available live on the company’s website, www.interpublic.com.

The conference call will be recorded and available for 30 days by calling (888) 296-6948 followed by the passcode 69781. Outside the United States, please call (203) 369-3028 followed by the passcode 69781. The call will also be archived and available in the investor relations section of the company’s website.

# # #

About Interpublic

Interpublic (NYSE: IPG) (www.interpublic.com) is a values-based, data-fueled, and creatively-driven provider of marketing solutions. Home to some of the world’s best-known and most innovative communications specialists, IPG global brands include Acxiom, Craft, FCB, FutureBrand, Golin, Initiative, IPG Health, IPG Mediabrands, Jack Morton, KINESSO, MAGNA, McCann, Mediahub, Momentum, MRM, MullenLowe Global, Octagon, UM, Weber Shandwick and more. IPG is an S&P 500 company with total revenue of $10.7 billion in 2024.

# # #

Contact Information

Tom Cunningham
(Press)
(212) 704-1326

Jerry Leshne
(Analysts, Investors)
(212) 704-1439

Monrovia, CA, April 10, 2025 (GLOBE NEWSWIRE) — Today, eXoZymes Inc. (NASDAQ: EXOZ) (“eXoZymes”) – a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals – announced its latest initiative – BioClick – a pioneering concept designed to enhance and accelerate the engineering of enzymes for advanced chemical reactions. Funded in part by a $300K grant from the National Institutes of Health (NIH), this project has the potential to revolutionize how medicines and other bio-based compounds are created.

At the heart of BioClick is a focus on group transfer reactions, a class of biochemical reactions that allow enzymes to precisely move small molecular chemical groups from one compound to another. Inspired by the 2022 Nobel Prize in Chemistry concept of Click Chemistry, often described as snapping LEGO pieces together, BioClick is now enabling new types of group transfers using custom enzymes. Among these, prenylation is a standout: a process where a small fatty molecular group is taken from a donor molecule and added to another drug compound to improve its function or how well it works in the body. This technique is especially promising in the development of more effective, targeted drugs and therapies, either as new drugs or as better versions of existing drugs.

“Our new BioClick approach not only boosts efficiency but opens the door to the biomanufacturing of rare and previously unthinkable target molecules that can be game-changers in medicine, nutrition, and other functional nutraceuticals. By building a complete tool set—from enzyme engineering to pilot scale synthesis, we’re setting a new standard for what can be done with bio-based click chemistry.” Said Dr. John Billingsley, PI on the recently awarded BioClick grant from NIH’s Small Business Innovation Research (SBIR) program. He adds, “If you consider directed evolution, which landed Dr. Francis H. Arnold the Nobel Prize in chemistry in 2018 as the first generation, and rational protein design as the second generation, we’re now introducing the third generation of enzyme engineering: Artificial Evolution.”

Critically, the BioClick tools also introduce new high-throughput screening capabilities, allowing researchers to test thousands of enzyme variations simultaneously. With the help of advanced tools like mass spectrometry and cutting-edge data analysis algorithms, eXoZymes can quickly identify which enzyme version works best for a given group transfer reaction – greatly enhancing the molecular level operation by quickly identifying the best-performing variants. This Artificial Evolution process dramatically reduces the time and cost required to develop the exozyme pathway that will produce a new or better drug.

“With our new BioClick tool set that incorporates artificial intelligence into our exozymes platform, coupled with our advanced enzyme engineering skills and high-throughput screening – which exponentially increases the rate of data acquisition – we now support the automated design of novel small molecules, that will lead to better medicines,” states Dr. Tyler Korman, co-founder and VP of Research at eXoZymes. He continues, “In other words, we’re not just fine-tuning our pathways of enzymes and exozymes for drug development – we’re unlocking a large new white space of small molecules previously inaccessible. We believe this has the potential to introduce not just new drugs but a valuable opportunity of taking existing drugs and making better versions of them.”

Acknowledgement
Research reported in this press release was supported by the National Institute of General Medical Sciences of the National Institutes of Health under award number R43GM157956. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

About eXoZymes
Founded in 2019, the company has developed a biomanufacturing platform that – as a historic first – offers the tools and insights to engineer, control and optimize nature’s own natural processes to produce chemical compounds, enabling the company’s partners to replace traditional chemical production methods with a new commercially scalable, sustainable, and eco-friendly alternative: exozymes.

Exozymes are advanced enzymes enhanced through AI and bioengineering to thrive in a bioreactor outside of living cells. Exozymes can replace toxic petrochemical processes and inefficient biochemical extraction with sustainable and scalable biosolutions that transform biomass into essential chemicals, medicines, and biofuels.

By freeing enzyme-driven chemical reactions from the limitations imposed by cells, exozyme biosolutions eliminate the scaling bottleneck that has hampered commercial success in the synthetic biology (SynBio) space, making exozymes the next generation of biomanufacturing.

While the company, eXoZymes Inc., has introduced “exozymes” as a scientific concept, they are not trademarking the concept, as they view it as a new nomenclature for wide adoption for this next generation of biomanufacturing that eXoZymes aims to pioneer and be the market leader of.

Learn more on exozymes.com.

eXoZymes Safe Harbor

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, which are based on certain assumptions and describe the company’s future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “would,” “could,” “seek,” “intend,” “plan,” “goal,” “project,” “estimate,” “anticipate,” “strategy,” “future,” “likely” or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the company’s strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Actual results could differ materially for a variety of reasons. You should carefully consider the risks and uncertainties described in the “Risk Factors” section of eXoZymes’ quarterly reports on Form 10-Q, annual reports on Form 10-K, and other documents filed by eXoZymes from time to time by the company with the Securities and Exchange Commission. These filings identify and address important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and eXoZymes assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. eXoZymes does not give any assurance that it will achieve its expectations. 

eXoZymes contact

Lasse Görlitz, VP of Communications
(858) 319-7135
[email protected]